findmyKOL
Clinical trialNCT02603146TerminatedPhase 2Interventional

Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis

SponsorNational Institute of Allergy and Infectious Diseases (NIAID)Enrollment144Healthy ParticipantsRheumatoid Arthritis (RA) Prevention
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to determine if hydroxychloroquine (HCQ) is safe and effective for the prevention of future onset of rheumatoid arthritis (RA) in individuals who have elevations of an autoantibody, anti-cyclic citrullinated peptide (anti-CCP3). The following recruitment strategies will be employed towards identifying healthy subjects with elevated anti-cyclic citrullinated peptide (anti-CCP3) levels: -Pre-screening: * first degree relatives of patients with rheumatoid arthritis (RA); * subjects at health-fairs; and * identification of subjects with elevated anti-CCP3 levels in the absence of inflammatory arthritis in rheumatology clinics.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

14 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of Alabama at Birmingham School of Medicine: Division of Clinical Immunology & Rheumatology

    Birmingham, Alabama, United States

  • Cedars Sinai Medical Center: Division of Rheumatology

    Los Angeles, California, United States

  • Ucla Medical Center: Division of Rheumatology

    Los Angeles, California, United States

  • University of California San Francisco, San Francisco General Hospital

    San Francisco, California, United States

  • University of Colorado School of Medicine: Division of Rheumatology

    Aurora, Colorado, United States

  • Emory Clinic at 1365 Clifton Road: Emory University School of Medicine

    Atlanta, Georgia, United States

  • Brigham & Women'S Hospital: Department of Medicine, Rheumatology, Immunology

    Boston, Massachusetts, United States

  • University of Massachusetts Memorial Medical Center: Rheumatology

    Worcester, Massachusetts, United States

  • University of Michigan Health System: Department of Internal Medicine, Division of Rheumatology

    Ann Arbor, Michigan, United States

  • Mayo Clinic, Division of Rheumatology

    Rochester, Minnesota, United States

  • University of Nebraska Medical Center: Division of Rheumatology

    Omaha, Nebraska, United States

  • Northwell Health

    Great Neck, New York, United States

  • Oklahoma Medical Research Foundation: Arthritis and Clinical Immunology Research Program

    Oklahoma City, Oklahoma, United States

  • University of Texas Southwestern Medical Center, Division of Rheumatic Diseases

    Dallas, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

HCQ PlaceboHydroxychloroquine →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
27 Apr 2016
Primary completion
1 Nov 2022
Completion
1 Nov 2022
Last update posted
12 Jun 2025
Registered enrollment
144
Registry id
NCT02603146
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.